44 results about "Ebola virus infection" patented technology

The present invention provides monoclonal antibodies, or antigen-binding fragments thereof, that bind to Ebola virus glycoproteins, pharmaceutical compositions comprising the antibodies and methods of use. The antibodies of the invention are useful for inhibiting or neutralizing Ebola virus activity, thus providing a means of treating or preventing Ebola virus infection in humans. In some embodiments, the invention provides for use of one or more antibodies that bind to the Ebola virus for preventing viral attachment and/or entry into host cells. The antibodies of the invention may be used prophylactically or therapeutically and may be used alone or in combination with one or more other anti-viral agents or vaccines.

The invention provides a nanometer antibody ebo7c2 for neutralizing Ebola viruses and application of the nanometer antibody to preparing medicines for preventing or treating Ebola virus infection. Amino acid sequences of the nanometer antibody are shown as SEQ ID NO:1, and nucleotide sequences for genes for encoding the nanometer antibody ebo7c2 are shown as SEQ ID NO:2. The nanometer antibody and the application have the advantages that CH2 structural domains m01s of human antibodies IgG1 are used as skeletons of the nanometer antibody, and amino acid of the nanometer antibody is different from amino acid sequences of the CH2 structural domains m01s in three loop zones; the nanometer antibody ebo7c2 can be bound with envelope proteins of the Ebola viruses; the nanometer antibody ebo7c2 has small molecular weights and is excellent in tissue permeability and ability of being bound with antigen epitopes with steric hindrance effects; the nanometer antibody is provided with the m01s skeletons and can be bound with FcRn, and the plasma half-life of the nanometer antibody can possibly reach 10 hours; the nanometer antibody ebo7c2 can be expressed in prokaryotic expression systems and is low in production cost and short in cycle.

The invention discloses an application of berbamine dihydrochloride in preparing Ebola virus inhibitor. According to the invention, the envelope glycoprotein (EBOV-GPcl) of the Ebola virus in an activated state is taken as a target point, and an antiviral active compound which is capable of binding with the EBOV-GPcl is obtained through structure-based virtual screening, and the compound is the berbamine dihydrochloride. The berbamine dihydrochloride can specifically inhibit the entry of the Ebola recombinant virus by combining with the target protein EBOV-GPcl so as to achieve the effect of resisting Ebola virus infection. The semi-maximal effect concentration (EC50) of the berbamine dihydrochloride against the EBOV is 0.49 micrometer, indicating that the berbamine dihydrochloride has a strong inhibitory effect on the EBOV.

The invention discloses a biological preparation used for preventing and controlling multiple genotypes of Ebola virus infection. A preparation method for the biological preparation comprises the following steps: preparing a mother liquor with a concentration of 1 M from acid anhydride and dimethyl sulfoxide; preparing a disodium hydrogen phosphate solution with a concentration of 0.1 M and applying the disodium hydrogen phosphate solution in preparation of a protein solution with a protein concentration of 20 mg/ml; adding the acid anhydride solution into the to-be-modified protein solution, wherein the concentration of added acid anhydride is allowed to be 12 mM, carrying out full and uniform mixing, adjusting the pH value of the protein solution to 9.0 and carrying out incubation at 25 DEG C for 20 min; repeating mixing of the acid anhydride and the protein solution until eventually, the final concentration of the acid anhydride in the protein solution is 60 mM and the pH value of the solution is 9.0, and carrying out incubation at 25 DEG C for 2 h to accomplish acid anhydride reaction; and filling a dialysis bag with the acid anhydridated protein solution, putting the dialysis bag in a phosphatic buffer with a pH value of 7.4 for dialysis for 48 h, filtering the acid anhydridated protein solution with a microfiltration membrane with a size of 0.45 [mu]m and carrying out preservation at 4 DEG C.

The present invention discloses applications of azithromycin and telithromycin in anti-Ebola virus infection, wherein the applications comprise applications of azithromycin or/and telithromycin in prevention or treatment of Ebola virus infection or combined applications of azithromycin or/and telithromycin and other anti-virus drugs.

The invention discloses applications of cardiac glycoside medicines in resisting Ebola virus infection. The infection stages comprise invasion, transcription and replication; the cardiac glycoside medicines comprise but are not limited to digoxin, digitoxin, lanatoside C and ouabain G. The four representative cardiac medicines can effectively prevent the Ebola virus from infecting host cells, thus a theoretical basis is provided for developing the antiviral compound medicines taking the cardiac glycoside as the main ingredient, and meanwhile, a scientific and technical support is provided for preventing and controlling the viral emerging infectious diseases.

The compositions and methods of the invention described herein provide treatments against Ebola virus infection by expressing gene(s) from the Ivory Coast ebolavirus (ICEBOV) species in a recombinant viral vector.

The invention discloses marker genes related with Ebola virus infection and applications thereof. The disclosed marker genes related with Ebola virus infection in blood are 10 following genes: DPAGT1 gene, GPR125 gene, GYP4B1 gene, PTPRK gene, NEK10 gene, NCAPD3 gene, ABCA13 gene, DNAH11 gene, KDELC1 gene, and MTA3 gene. The expression amount of the 10 genes in EBOV infected patients is obviously increased, compared with non-EBOV infected patients, and thus the 10 molecules can be used as biological molecular markers applied to the clinical diagnosis of EBOV infected patients.

The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.

The invention discloses characteristic miRNAs in Ebola virus infected blood and an application of the characteristic miRNAs. The miRNAs in blood related to Ebola virus infection provided by the invention include hsa miR 151a 5p, hsa miR 744 5p, hsa miR 423 5p, hsa miR 331 3p, hsa miR 1306 5p, hsa miR 1285 3p, hsa miR 185 5p, hsa miR 550a 5p, hsa miR 3940 3p, hsa miR 574 5p and hsa miR 941; and the eleven miRNAs, as biological molecular markers, are applicable to clinical diagnosis of EBOV infection.

This disclosure is directed to compositions and methods for utilizing the boundaries of the C-terminal domains of Nucleoprotein from Zaire Ebola virus as highly stable recombinant protein antigens to generate antibodies for diagnosis and treatment of Ebola virus infection.

The present invention relates to antibodies or fragments thereof that specifically bind to glycoprotein (GP) of Ebola virus, and to their use for treating and diagnosing Ebola virus disease.

The present invention relates to a 2,3-epoxy succinyl derivative, a preparation method and a use thereof, in particular, the present invention relates to a compound represented by Formula (1), a racemate or an optical isomer thereof, a solvate thereof, or a pharmaceutically acceptable salt thereof. The compound according to the present invention has good inhibitory activity and/or selectivity against cathepsin, especially Cathepsin B, can be used in the treatment of multiple diseases associated with cathepsin, for example, osteoporosis, rheumatoid arthritis and osteoarthritis that are associated with Cathepsin K, Ebola virus infection, a degenerative disease and an autoimmune disease that are associated with Cathepsin L, S, especially Cathepsin B-related tumor diseases, such as gastric cancer, cervical cancer, lung cancer, breast cancer, prostate cancer, bladder cancer, colon cancer, neuroglioma, and melanoma.

Ebola virus vaccines comprising nucleic acid molecules encoding Ebola viral proteins are provided. In one embodiment, the nucleic acid molecule encodes the transmembrane form of the viral glycoprotein (GP). In another embodiment, the nucleic acid molecule encodes the secreted form of the viral glycoprotein (sGP). In yet another embodiment, the nucleic acid molecule encodes the viral nucleoprotein (NP). Methods for immunizing a subject against disease caused by infection with Ebola virus are also provided.

The invention provides an application of triparanol to resisting Ebola virus infection, and particularly relates to an application of triparanol to blocking Ebola invasion infection. A theoretical basis is provided for developing an antiviral combined drug taking the triparanol as a main component, and technical support is provided for prevention and control of viral emerging infectious diseases.

The invention belongs to the technical field of medicines. In particular, the invention relates to application of a bicyclic amine compound having a structure shown by formula (I) in prevention and/ortreatment of Ebola virus infections or diseases (e.g., Ebola hemorrhagic fever) caused by the Ebola virus infections. The present application also relates to application of a bicyclic amine compoundhaving a structure shown by formula (I) in preparation of pharmaceutical compositions for preventing and/or treating Ebola virus infections or the diseases (e.g., Ebola hemorrhagic fever) caused by the Ebola virus infections.

The invention relates to application of an FRAX597 compound in preparation of a medicine for preventing Ebola virus infection or treating Ebola virus diseases. Researches show that after cells are treated with the FRAX597 inhibitor compound of serine/threonine kinase PAK2 (Gene ID: 5062), replication of the Ebola virus in the cells is remarkably reduced, and proliferation of the Ebola virus is inhibited. CCK8 is used for detecting the cytotoxicity of the FRAX597, and it is proved that the FRAX597 shows extremely low or even negligible cytotoxicity under the condition that the concentration is controlled. Therefore, the FRAX597 can be used as an active ingredient for preparing a candidate medicine for treating and resisting the Ebola virus disease.